Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of SCT630 in Healthy Subjects
NCT03917628Phase 1Completed
- Sponsor
- Sinocelltech Group Limited
- Start
- May 2019
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SCT630 in plaque psoriasis, rheumatoid arthritis (RA), ankylosing spondylitis (AS) and 1 more (2 arms), sponsored by Sinocelltech Group Limited. Primary endpoints: Area Under the Serum Concentration-Time Curve from Time Zero to the Last Measurable Concentration at Day 71 and Maximum Observed Serum Concentration at Day 71. Started May 2019; status: completed.
02
Drugs
SCT630
03
Conditions
plaque psoriasisrheumatoid arthritis (RA)ankylosing spondylitis (AS)Crohn's disease
Beyond the preview
Go deeper on NCT03917628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03917628.